OBT has entered a multi-year partnership with Roche to discover antibody-based therapeutics for cancer treatment.

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

Cognizant (NASDAQ: CTSH) announced advancements built on NVIDIA AI aimed at accelerating the cross-industry adoption of AI ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

An Oxford University spinout has secured £14 million in funding to advance its "transformative" AI imaging technology in ...

Oxford BioTherapeutics has partnered with Roche to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer.

Oxford BioTherapeutics (OBT) has lined up another big pharma partner for its drug discovery platform, agreeing to work with Roche on the hunt for new antibody therapeutics for cancer in a deal worth ...

Oxford BioTherapeutics inks multi-year collaboration with Roche to discover novel targets for antibody-based therapeutics to treat cancer: Oxford, UK Thursday, March 20, 2025, 17: ...

Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based ...

Work to create a platform for Oxford rail station has been delayed by ongoing efforts to get Botley Road reopened. Network Rail closed Botley Road at the rail bridge as part of a £161m scheme to ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

At Fierce Healthcare, we keep track of all the venture capital being funneled into the health tech and digital health ...